Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Identification

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    691 result(s) found for: Identification. Displaying page 9 of 35.
    EudraCT Number: 2018-001036-21 Sponsor Protocol Number: PCaRestaging-PET/MR Start Date*: 2020-03-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Phase II monocentric study on prostate cancer restaging using PET/MR with innovative radiotracers
    Medical condition: Radically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002478-20 Sponsor Protocol Number: PRECISESTUDY Start Date*: 2022-03-31
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA
    Full Title: IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY.
    Medical condition: PSORIATIC ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003738-40 Sponsor Protocol Number: BO21129 Start Date*: 2008-08-07
    Sponsor Name:ROCHE
    Full Title: A phase II Biomarker Identification Trial for Erlotinib (Tarceva) in Patients with Advanced Pancreatic Carcinoma.
    Medical condition: Advanced Pancreatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033633 Pancreatic neoplasms malignant (excl islet cell and carcinoid) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) LV (Completed) DE (Completed) LT (Completed) BG (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2017-001982-26 Sponsor Protocol Number: OZM-063 Start Date*: 2018-04-26
    Sponsor Name:The Hospital for Sick Children
    Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma...
    Medical condition: Unresectable or progressive low grade glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-001034-11 Sponsor Protocol Number: CLOU064A2303B Start Date*: 2022-11-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to assess the efficacy, safety and tolerabili...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) DE (Trial now transitioned) AT (Completed) HU (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2007-004586-17 Sponsor Protocol Number: UV 2007/01 Start Date*: 2008-04-04
    Sponsor Name:OM PHARMA
    Full Title: Multicentre, double-blind, placebo controlled randomised clinical study of URO-VAXOM® in female patients suffering from uncomplicated recurrent urinary tract infections
    Medical condition: Uncomplicated recurrent urinary tract infections
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038140 Recurrent urinary tract infection LLT
    Population Age: Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000028-15 Sponsor Protocol Number: TC-023-IM Start Date*: 2007-01-26
    Sponsor Name:Nycomed Danmark ApS
    Full Title: A randomised, open label, parallel-group, multi-centre trial to compare the efficacy and safety of TachoSil versus standard haemostatic treatment in the cardiovascular surgery
    Medical condition: Supportive haemostatic treatment in patients having elective surgery on the heart, the ascending aorta or arch, requiring pulmonary bypass procedure.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) DK (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002988-25 Sponsor Protocol Number: ML-DS2018 Start Date*: Information not available in EudraCT
    Sponsor Name:Gesellschaft für Pädiatrische Onkologie & Hämatologie (GPOH gGmbH)
    Full Title: Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018
    Medical condition: Myeloid Leukemia in Children with Down Syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004449-18 Sponsor Protocol Number: HEP201 Start Date*: 2019-04-10
    Sponsor Name:Promethera Biosciences
    Full Title: Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH).
    Medical condition: NASH is characterized by steatosis, inflammation and cytological ballooning with varying amounts of fibrosis. Patients with NASH are at risk of cardiovascular morbidity and mortality. In chronic li...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10031743 Other chronic nonalcoholic liver disease LLT
    20.0 10019805 - Hepatobiliary disorders 10019708 Hepatic steatosis PT
    20.0 10019805 - Hepatobiliary disorders 10041970 Steatosis hepatic LLT
    20.0 10019805 - Hepatobiliary disorders 10019669 Hepatic fibrosis and cirrhosis HLT
    20.0 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    20.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    20.0 10019805 - Hepatobiliary disorders 10009213 Cirrhosis of liver LLT
    20.1 10019805 - Hepatobiliary disorders 10064704 Decompensated cirrhosis LLT
    20.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10076331 Steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-000239-34 Sponsor Protocol Number: PONTIACII Start Date*: 2015-12-30
    Sponsor Name:Medizinische Universität Wien
    Full Title: NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial
    Medical condition: The purpose of this study is to evaluate the effect of high dose Renin-Angiotensin System (RAS)-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000608-14 Sponsor Protocol Number: 1.0/170119 Start Date*: Information not available in EudraCT
    Sponsor Name:Tartu University Hospital
    Full Title: Prospective validation of individualized Bayesian dose optimization tool DosOpt for Vancomycin treatment in neonates.
    Medical condition: In neonatal population wide inter-and intra-individual variability of pharmacokinetics makes extremely difficult to ensure optimal exposure of vancomycin with standard regimens. On average >50% of ...
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003724-79 Sponsor Protocol Number: 17SM4152 Start Date*: 2018-07-10
    Sponsor Name:Imperial College London
    Full Title: IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)
    Medical condition: Alcoholic Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-006686-32 Sponsor Protocol Number: EC07/90573 Start Date*: 2008-05-22
    Sponsor Name:FUNDACIÓN INVESTIGACIÓN BIOMEDICA DEL HOSPITAL CLINICO SAN CARLOS
    Full Title: Identificación de biomarcadores proteicos asociados a resistencia a la aspirina y a tienopiridinas en pacientes con cardiopatía isquémica establecida. (ESTUDIO BIRAT). Identification of new protei...
    Medical condition: To determine proteins in plasma, leukocytes and platelets associated with aspirin resistance syndrome in stable coronary artery disease patients that may allow us to identify them.It is probably th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007652-34 Sponsor Protocol Number: Bismuth-PBH-2008 Start Date*: 2009-03-05
    Sponsor Name:Herlev Hospital, Dept. of haematology (L121)
    Full Title: Kan mineraltilskud med bismuth mindske toksiciteten af kemoterapi og strålebehandling? En klinisk prospektiv, dobbeltblind randomiseret undersøgelse af patienter med hæmatologiske sygdomme som modt...
    Medical condition: Malignant diseases of the blood requiring chemotherapy and/or radiation therapy of head and neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001856-12 Sponsor Protocol Number: NT-12331-5 Start Date*: 2011-08-11
    Sponsor Name:The Motol University Hospital
    Full Title: Early assessment of effectivness of neoadjuvant chemotherapy for carcinoma of the esophagus and esophago-gastric junction using FDG-PET/CT.
    Medical condition: adenocarcinoma of the esophagus and esophago-gastric junction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008721-29 Sponsor Protocol Number: KYT62121/2008-01 Start Date*: 2009-11-19
    Sponsor Name:Merck Selbstmedikation GmbH
    Full Title: Double-blind, randomised, multi-centre, placebo-controlled clinical trail to investigate the efficacy and safety of a combination of comfrey root extract plus methyl nicotinate versus a preparation...
    Medical condition: Acute upper or low back pain as described in the note for guidance on clinical investigation of medical products for treatment of Nociceptive Pain (CPMP/EWP/612/00. Nov. 21, 2002)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000683 Acute back pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001017-13 Sponsor Protocol Number: CNIO-GI-01-2011 Start Date*: 2011-08-08
    Sponsor Name:CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS
    Full Title: Phase II trial of individualized selection of chemotherapy in patients with advanced pancreatic carcinoma based on the identification of therapeutic targets in tumor tissue
    Medical condition: Advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059326 Pancreatic carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000389-12 Sponsor Protocol Number: 3.0 Start Date*: 2013-09-11
    Sponsor Name:Cardiff University
    Full Title: ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): A Randomised Double-blind Placebo Controlled Trial
    Medical condition: Aggression and challenging behaviour in adults with learning disabilities
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000696-27 Sponsor Protocol Number: n/a Start Date*: 2015-08-06
    Sponsor Name:prof. dr. M.A.F.J. van de Laar
    Full Title: Anakinra versus treatment as usual in the treatment of acute gout
    Medical condition: Gout
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018205-43 Sponsor Protocol Number: 0928 Start Date*: 2010-06-30
    Sponsor Name:Oncology Department
    Full Title: A clinical phase I / II trial of Belinostat in combination with Erlotinib in patients with non-small cell lung cancer.
    Medical condition: Metastatic non small lungcancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 20:31:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA